$71.82
0.210.29%
al cierre: -
$72.01
0.190.26%
After hour: 7:40 PM EDT
Comments
Loading...
Orientación y previsiones
Halozyme Therapeutics emite una orientación sobre las ganancias por acción y los ingresos futuros, lo que ofrece a los inversores una idea de cuánto espera ganar la empresa en los próximos períodos.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
08/05/2025 | HALO | Halozyme Therapeutics | FY | 2025 | $6.00 | $6.40 | $5.50 | $1.27B | $1.35B | $1.25B | |
05/06/2025 | HALO | Halozyme Therapeutics | FY | 2025 | $5.30 | $5.70 | $5.50 | $1.20B | $1.28B | $1.25B | |
02/18/2025 | HALO | Halozyme Therapeutics | FY | 2025 | $4.95 | $5.35 | $5.50 | $1.15B | $1.23B | $1.25B | |
01/08/2025 | HALO | Halozyme Therapeutics | FY | 2024 | $4.00 | $4.20 | $4.13 | $970.00M | $1.02B | $1.00B | |
01/08/2025 | HALO | Halozyme Therapeutics | FY | 2025 | $4.95 | $5.35 | $5.50 | $1.15B | $1.23B | $1.25B | |
10/31/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $4.00 | $4.20 | $4.13 | $970.00M | $1.02B | $1.00B | |
08/06/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.65 | $4.05 | $4.13 | $935.00M | $1.01B | $1.00B | |
06/06/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.65 | $4.05 | $4.13 | $935.00M | $1.01B | $1.00B | |
05/07/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.55 | $3.90 | $4.13 | $915.00M | $985.00M | $1.00B | |
02/20/2024 | HALO | Halozyme Therapeutics | FY | 2024 | $3.55 | $3.90 | $3.51 | $915.00M | $985.00M | $961.09M | |
01/17/2024 | HALO | Halozyme Therapeutics | FY | 2023 | $2.77 | $2.80 | $2.74 | $827.00M | $832.00M | $835.69M | |
11/06/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.70 | $2.80 | $2.65 | $825.00M | $845.00M | $835.91M | |
08/08/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.65 | $2.75 | $2.61 | $825.00M | $845.00M | $823.06M | |
05/09/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.57 | $815.00M | $845.00M | $833.00M | |
03/15/2023 | HALO | Halozyme Therapeutics | FY | 2023 | — | — | — | $815.00M | $845.00M | $829.01M | |
02/21/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.78 | $815.00M | $845.00M | $868.12M | |
01/10/2023 | HALO | Halozyme Therapeutics | FY | 2023 | $2.50 | $2.65 | $2.90 | $815.00M | $845.00M | $892.47M | |
11/08/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.10 | $2.25 | $2.04 | $655.00M | $685.00M | $661.33M | |
08/09/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.10 | $2.25 | $2.23 | $655.00M | $685.00M | $610.87M | |
05/10/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.23 | $530.00M | $560.00M | $566.18M | |
04/13/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.18 | $530.00M | $560.00M | $553.27M | |
02/22/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.18 | $530.00M | $560.00M | $554.20M | |
01/10/2022 | HALO | Halozyme Therapeutics | FY | 2022 | $2.05 | $2.20 | $2.68 | $530.00M | $560.00M | $569.39M | |
11/02/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.90 | $2.00 | — | $430.00M | $445.00M | — | |
08/09/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.85 | $2.00 | $1.41 | $425.00M | $445.00M | $404.56M | |
05/10/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.55 | $1.70 | $1.55 | $375.00M | $395.00M | $389.96M | |
02/23/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.40 | $1.55 | $1.70 | $375.00M | $395.00M | $400.15M | |
01/13/2021 | HALO | Halozyme Therapeutics | FY | 2020 | $0.90 | $0.95 | $0.93 | $265.00M | $275.00M | $265.30M | |
01/11/2021 | HALO | Halozyme Therapeutics | FY | 2021 | $1.40 | $1.55 | $1.79 | $375.00M | $395.00M | $403.71M | |
11/23/2020 | HALO | Halozyme Therapeutics | FY | 2020 | $0.90 | $0.95 | $0.86 | $265.00M | $275.00M | $255.12M |
PREGUNTAS FRECUENTES
¿Cuál es la orientación más reciente de Halozyme Therapeutics (HALO)?
La orientación más reciente para Halozyme Therapeutics (HALO) se informó el agosto 5, 2025 para el año completo 2025. La empresa proporcionó una guía de ganancias por acción en el rango de $6.00 a $6.40, en comparación con el EPS estimado de $5.50. Además, Halozyme Therapeutics pronosticó ingresos entre $1.27B y $1.36B para el trimestre.
Explora orientación y previsión sobre todos los valores.